Why Hyaluronic Acid Is the Preferred Choice for Tear Trough and Eye Rejuvenation

Hyaluronic acid is favoured for tear trough and eye rejuvenation because it occurs naturally in the body, attracts and retains moisture, integrates gently with delicate periorbital tissue, and can be dissolved with an enzyme called hyaluronidase if adjustment is needed. These properties make it uniquely suited to the under-eye area.

Hyaluronic acid is favoured for tear trough and eye rejuvenation because it occurs naturally in the body, attracts and retains moisture, integrates gently with delicate periorbital tissue, and can be dissolved with an enzyme called hyaluronidase if adjustment is needed. These properties make it uniquely suited to the under-eye area.

Pick up any conversation about under-eye hollows and one term appears consistently: hyaluronic acid. Yet the reasons it dominates tear trough treatment go well beyond familiarity or fashion. The under-eye area is one of the most anatomically demanding sites for any injectable material, and the choice of filler substance is not a minor detail. It shapes how the outcome looks, how safely the treatment can be adjusted, and what options remain open if circumstances change.

If you have been researching under-eye hollows and are building an understanding of what treatment involves, the detailed guide to understanding under-eye hollows before considering dermal filler covers the broader landscape, from how hollows develop to what a careful assessment evaluates. This article goes deeper into one specific question: why hyaluronic acid, and not something else?

The answer involves biology, material science, anatomy, and the practical realities of working in a region where the margin for error is narrow and the consequences of getting it wrong are visible every time you look in a mirror. Understanding these reasons helps you ask better questions during your assessment and make a more informed decision about whether treatment is right for you.

—

What is hyaluronic acid and why does your body already recognise it?

How hyaluronic acid functions in skin and connective tissue

Hyaluronic acid is a naturally occurring polysaccharide, a type of sugar molecule, found throughout the human body. It is particularly concentrated in the skin, joint fluid, and connective tissue. Its primary function is to bind and retain water: a single molecule can hold many times its own weight in moisture, which is why it plays such a central role in keeping skin hydrated, plump, and resilient.

Within the skin, hyaluronic acid sits in the extracellular matrix, the structural scaffolding that surrounds and supports skin cells. It works alongside collagen and elastin to maintain volume, elasticity, and mechanical integrity. As you age, the body’s natural production of hyaluronic acid declines. This contributes to the loss of skin hydration, reduced volume, and the gradual hollowing that becomes visible in areas like the tear trough.

In connective tissue more broadly, hyaluronic acid acts as a lubricant and shock absorber. Its ability to change viscosity under pressure, becoming more fluid when compressed and more gel-like when still, is a property that turns out to be highly relevant when considering how a filler material needs to behave beneath the thin, mobile skin of the lower eyelid.

Why natural occurrence matters when choosing a filler material

The fact that hyaluronic acid is already present in your body is not simply a reassuring talking point. It has direct clinical relevance. Because the molecule is structurally identical across species and is not inherently foreign to human tissue, the immune system does not typically mount a significant response to it. Allergic reactions to hyaluronic acid-based dermal fillers are reported, but they are rare. This stands in contrast to some older filler materials derived from animal sources, which carried a higher risk of hypersensitivity and required pre-treatment skin testing.

The body also has natural mechanisms for breaking down hyaluronic acid. An enzyme called hyaluronidase, which exists endogenously in your tissues, gradually metabolises hyaluronic acid over time. This is why hyaluronic acid fillers are not permanent, and it is also why they can be dissolved intentionally when needed, a property explored in detail later in this article.

For the tear trough specifically, biocompatibility matters more than almost anywhere else on the face. The periorbital tissues are highly vascular, closely associated with important anatomical structures, and visible at very close range. A material that integrates smoothly, behaves predictably, and is metabolised through normal biological pathways is not just preferable in this location. It is, in the view of most clinicians working in this area, essential.

Q: Is the hyaluronic acid used in fillers the same as what my body produces?
The hyaluronic acid used in dermal fillers is chemically identical to the molecule your body produces naturally. The key difference is that it is cross-linked to slow its breakdown, which is what gives it volume-restoring properties rather than simply being reabsorbed within days. The biological recognition remains the same.

—

Why is the under-eye area particularly demanding for filler materials?

The anatomical characteristics that make periorbital tissue unique

The skin directly beneath the eye is the thinnest on the face, measuring roughly half the thickness of skin elsewhere. Beneath it lies a layer of loose areolar tissue with very little fat padding, followed by the orbicularis oculi muscle, which is responsible for eye closure and contributes to the dynamic movement of the lower lid. Below that sits the orbital septum, and beyond it, the orbital fat compartments.

This layered, mobile structure means that anything placed beneath the skin is subject to constant movement. Every blink, every expression, every shift in fluid balance affects what is happening in the periorbital tissue. A filler material that is too firm will resist this movement and may become palpable or visible as a lump. One that is too soft may migrate or fail to provide the structural support needed to correct the hollow.

The vascularity of the periorbital region also demands respect. The area is supplied by branches of both the ophthalmic artery and the facial artery, and the venous drainage is interconnected with the orbital vasculature. This anatomy underpins why vascular complications, though rare, carry particular significance around the eyes, and why ultrasound technology is increasingly used in assessment and treatment planning to map vessels before injection.

The tear trough itself sits at the junction of the lower eyelid and the cheek, a transition zone where the anatomy shifts from orbital to facial structures. Correcting a hollow here requires placing material precisely in a location where the margin between too superficial and too deep is genuinely narrow.

How hyaluronic acid properties address the specific challenges of this region

Hyaluronic acid gels behave in a way that suits this demanding environment. They are soft enough to move with the tissue rather than against it, yet structured enough to provide the volumetric correction needed. When formulated appropriately for the periorbital region, they integrate with the surrounding tissue rather than sitting as a discrete foreign body.

The hygroscopic nature of hyaluronic acid, its ability to attract and bind water, means it contributes to the appearance of hydration and brightness in the under-eye area. Many people notice that well-placed tear trough filler does not just address the hollow itself but also improves the overall quality and luminosity of the skin in that zone.

Critically, hyaluronic acid does not stimulate significant fibrosis or scarring in the surrounding tissue. Some other filler materials can trigger a foreign body response that leads to granuloma formation or tissue changes that are difficult to manage. In the periorbital area, where any irregularity is immediately visible and where revision options are limited, this tissue compatibility is not a minor advantage.

—

How do different hyaluronic acid formulations differ, and does it matter for the eyes?

Cross-linking, cohesivity, and what these terms mean in practice

Not all hyaluronic acid fillers are equivalent. The raw molecule is the same, but manufacturers modify it through a process called cross-linking, which creates bonds between individual hyaluronic acid chains. These cross-links slow the enzymatic breakdown of the gel and give it structural properties that plain, uncrosslinked hyaluronic acid does not have.

The degree and type of cross-linking determines how firm or soft the resulting gel is, how long it is likely to last, and how it behaves under pressure. A highly cross-linked filler is denser and more resistant to compression. It holds its shape well and is suited to areas requiring significant structural support, such as the chin or jawline. A lightly cross-linked or more hydrophilic formulation is softer and more spreadable, integrating with tissue rather than sitting within it as a discrete bolus.

Cohesivity refers to how well the gel holds together as a unit. A highly cohesive filler maintains its shape and is less likely to spread beyond the injection point. A less cohesive gel flows more readily and distributes across a wider area. For the tear trough, where precise placement matters enormously and where any excess material will show, cohesivity is a relevant consideration.

Q: What does it mean when a hyaluronic acid filler is described as ‘cross-linked’?
Cross-linking refers to the chemical bonds formed between hyaluronic acid chains during manufacturing. These bonds slow the natural breakdown of the gel, extending how long it lasts in tissue. The extent of cross-linking also influences the firmness, cohesivity, and behaviour of the filler. More cross-linking generally means a firmer, longer-lasting product. Less cross-linking produces a softer gel that integrates more readily with surrounding tissue.

Why formulation selection is a clinical decision, not a product preference

The range of hyaluronic acid formulations available means that selecting the right one for the tear trough is a genuine clinical decision, not simply a matter of brand preference. The ideal formulation for the periorbital region is typically one that is soft enough not to create visible ridging or palpable lumps beneath thin skin, yet structured enough to provide meaningful volumetric correction.

It is also worth noting that the same practitioner may choose different formulations for different people, depending on the depth of the hollow, the thickness of the overlying skin, the degree of correction needed, and the individual’s tissue characteristics. This is one reason why a careful assessment before any treatment is not a formality. It directly informs which material is appropriate and how it should be placed.

At Dr Alek Nikolic’s practice, formulation selection is guided by the clinical findings of the assessment, including skin quality evaluation and, where relevant, ultrasound-assisted tissue assessment, rather than by a fixed protocol applied uniformly.

—

What does reversibility mean in practice, and why does it matter under the eyes?

How hyaluronidase works and when it is used

Hyaluronidase is an enzyme that breaks down hyaluronic acid by cleaving the bonds between sugar units in the molecule. It exists naturally in the body and is also available as an injectable preparation. When introduced into tissue containing hyaluronic acid filler, it acts relatively quickly, beginning to dissolve the gel within minutes to hours, though the full effect typically becomes apparent over a day or two.

In clinical practice, hyaluronidase is used in two distinct contexts. The first is elective: a patient is unhappy with the outcome of their filler treatment, whether due to over-correction, asymmetry, or a change of preference, and dissolution is the chosen solution. The second is urgent: a vascular complication has occurred, and hyaluronidase is used to dissolve filler that may be compromising blood supply to the surrounding tissue. In the latter scenario, prompt access to hyaluronidase and the knowledge to use it correctly is a genuine safety consideration.

Q: Can hyaluronic acid filler under the eyes be removed if I am unhappy with the outcome?
Yes. One of the most clinically significant advantages of hyaluronic acid-based dermal fillers is that they can be dissolved using hyaluronidase. If you are unhappy with the outcome, whether due to asymmetry, over-correction, or a change of preference, the filler can be partially or fully dissolved. This does not mean dissolution is always straightforward or without nuance, but the option exists in a way that it does not with permanent or semi-permanent materials.

Reversibility as a safety consideration, not just a correction tool

The ability to dissolve hyaluronic acid filler is often discussed primarily in terms of correcting unsatisfactory outcomes. This is understandable, but it understates the safety significance of reversibility in the periorbital region specifically.

The tear trough is in close proximity to the eye itself and to the vascular supply of the orbital structures. Whilst serious vascular complications are rare when treatment is performed by a clinician with appropriate training and access to diagnostic technology, the consequences of such events in this region are serious enough that the ability to rapidly dissolve a hyaluronic acid filler represents a meaningful safety advantage over materials that cannot be removed.

This is one reason why the management of tear trough filler complications is an area that deserves serious attention, and why choosing a practitioner who holds hyaluronidase on-site and is trained in its emergency use is not a minor consideration. The reversibility of hyaluronic acid is not just a reassurance for patients who change their minds. It is a genuine component of the safety framework surrounding treatment in this area.

Q: How long does hyaluronic acid filler typically last in the tear trough area?
Hyaluronic acid filler in the tear trough area typically lasts between nine and eighteen months, though individual variation is considerable. Factors including the specific formulation used, the volume placed, your metabolism, and how active the surrounding musculature is all influence longevity. Many people find that filler in this area lasts somewhat longer than in higher-movement zones like the lips, because the tear trough is a relatively static location.

—

How does hyaluronic acid compare to other filler materials for the under-eye area?

Why permanent and semi-permanent fillers are generally avoided around the eyes

Several categories of filler material exist beyond hyaluronic acid. These include calcium hydroxylapatite, poly-L-lactic acid, polymethylmethacrylate, and various permanent or semi-permanent gel formulations. Each has legitimate applications in aesthetic medicine. The question here is not whether these materials are safe in general, but whether they are appropriate for the specific demands of the periorbital region.

Calcium hydroxylapatite is a biostimulatory filler that works partly by stimulating collagen production. It is well suited to areas requiring structural support and volume, such as the cheeks or temples. However, it cannot be dissolved with hyaluronidase, and its firmer consistency makes it less forgiving beneath the thin, mobile skin of the lower eyelid. Irregularities that might be acceptable in a thicker-skinned area become visible and palpable here.

Poly-L-lactic acid is a collagen biostimulator rather than a direct volume filler. It works gradually by stimulating the body’s own collagen production. Whilst it has valuable applications in facial volume restoration, it is not typically used in the tear trough because the gradual, diffuse collagen stimulation it produces is difficult to control with the precision the periorbital area demands.

Permanent fillers present a different set of concerns. Any material that cannot be removed or dissolved carries a long-term risk profile that is difficult to justify in an area as anatomically complex and visually prominent as the under-eye region. Tissue changes, granuloma formation, and migration are all potential long-term complications of permanent materials, and none of these can be addressed by dissolution. Surgical removal is often the only recourse, and it carries its own risks and limitations.

What the evidence and clinical consensus currently indicate

Clinical consensus amongst practitioners working in facial aesthetics broadly supports hyaluronic acid as the material of choice for tear trough treatment. This reflects not just the properties of the material itself, but the practical realities of working in a region where correction, adjustment, and safety management all benefit from reversibility.

The evidence base for tear trough treatment is still developing, as is the case across much of aesthetic medicine, where randomised controlled trials are less common than in pharmaceutical medicine. However, the clinical experience accumulated across the field, combined with the well-characterised properties of hyaluronic acid, supports its preferred status in this application.

It is also worth noting that hyaluronic acid is not without its own considerations in the tear trough. The Tyndall effect, a bluish discolouration caused by superficially placed filler refracting light, is a known complication of hyaluronic acid specifically, and one that underlines why placement depth and formulation choice matter. This is not a reason to avoid the material. It is a reason to ensure treatment is performed by someone with the anatomical knowledge and technical skill to place it correctly.

Q: Why is hyaluronic acid specifically chosen for tear trough treatments rather than other filler types?
Hyaluronic acid is chosen for tear trough treatment because its softness, biocompatibility, tissue integration, and reversibility align with the specific demands of the periorbital region. Other filler materials, whilst effective in other facial areas, either cannot be dissolved if problems arise, are too firm for the thin overlying skin, or produce effects that are too diffuse to allow precise correction in a narrow anatomical zone.

—

Bringing it together: the case for a considered, material-informed approach

The preference for hyaluronic acid in tear trough and eye rejuvenation is not arbitrary. It reflects a convergence of biological compatibility, material properties, anatomical demands, and safety considerations that make it the most clinically defensible choice for this specific application.

Understanding why the material matters helps you engage more meaningfully with your own assessment. When you sit down with a practitioner to discuss under-eye treatment, the conversation should include not just whether you are suited to filler, but which formulation is appropriate for your anatomy, how it will be placed, and what the plan is if adjustment is ever needed. These are not excessive questions. They are the right ones.

At Dr Alek Nikolic’s practice, the assessment process is designed to answer exactly these questions before any treatment decision is made. Ultrasound technology supports the evaluation of your periorbital anatomy, including vascular mapping where relevant. The choice of formulation follows from the clinical findings of that assessment, not from a fixed menu. And the availability of hyaluronidase on-site is treated as a standard safety requirement, not an afterthought.

If you are considering tear trough treatment or simply want to understand whether it is an appropriate option for you, the starting point is a careful assessment. The material science discussed in this article matters, but it matters most in the hands of someone who applies it with the anatomical knowledge and clinical judgement the periorbital area demands.

To begin that conversation, an assessment with Dr Alek Nikolic will give you an honest, evidence-based picture of what treatment can realistically offer for your specific anatomy and concerns, without commitment to a particular outcome before the evaluation is complete.